Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes drug delivery strategies to hair follicles, highlighting physicochemical factors affecting penetration and the use of stimuli-responsive particulate carriers, but reports no new clinical findings.

The researchers reported that dermatological side effects from chemotherapy for women's cancers are common and significantly affect quality of life.

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.

This study found that African-American and Hispanic patients with systemic lupus erythematosus reported higher levels of unmet psychological needs and may be more prone to depression and anxiety due to SLE-related challenges.

Minoxidil absorbs poorly through skin, with low risk of side effects at 1-2% concentration.

This review examines androgen replacement therapy in women for treating androgen deficiency symptoms and reports no new clinical results, while noting potential safety within a specific dose range.

This study found that taking a daily oral dose of 50mg DHEA for one year had no significant impact on blood lipids, insulin sensitivity, or the endometrium in postmenopausal women with low libido.

This report describes an 11-year-old boy with Netherton syndrome who developed Cushing syndrome after using low-potency hydrocortisone ointment extensively, highlighting caution with long-term topical treatments in such conditions.

In this study, a combination of irinotecan and cetuximab showed varied response rates in metastatic colorectal cancer patients, with manageable skin toxicity that improved quality of life when treated collaboratively by oncology and dermatology teams.

This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.

In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.

This editorial discusses the hormonal basis of catamenial epilepsy, particularly focusing on the roles of progesterone and neurosteroids, and presents no new research findings.

This article reviews the association between hepatitis C virus and systemic disorders like mixed cryoglobulinemia, highlighting potential autoimmune side effects from interferon-a2b treatments, and reports no new clinical results.

Minoxidil solution can cause skin irritation and allergies in some users.

This study reported a drug-induced pityriasis rubra pilaris-like eruption in a patient treated with sorafenib, suggesting a possible effect of sorafenib on keratinocyte biology.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This review discusses the various potential causes of hair loss in patients with inflammatory bowel disease, including telogen effluvium from disease flares, but provides no prevalence data; the authors outline a practical assessment and management approach.

This study observed that oral mTOR inhibitors frequently cause dermatological side effects, such as mouth ulcers and acneiform eruptions, but these rarely require stopping the treatment.

This report describes five cases where sudden akathisia occurred in female patients with bipolar disorder after a ziprasidone dose reduction, emphasizing potential unexpected side effects of second-generation antipsychotics.

In this study, 96% of children with CNS tumors receiving MAPK and mTOR inhibitors experienced common, treatable skin reactions, occasionally requiring therapy adjustments.

This study found that 2% minoxidil solution significantly increased nonvellus hair count in men with male pattern baldness compared to placebo during a 48-week trial.

This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.

This review suggests that while finasteride for male pattern hair loss was previously considered safe, there is now evidence associating 5-α reductase inhibitors with significant sexual and reproductive side effects.

This study reports that while topical minoxidil treatment showed a response in less than 40% of men after 24 weeks, oral finasteride stopped hair loss in over 80% of patients at 12 months; perceived sexual side effects of the latter may limit its use.

This article provides an overview of acne vulgaris, discussing its causes, presentation, and psychosocial impact, but it reports no new research findings or clinical results.

This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study highlights the significant impact of eyebrow and eyelash loss during chemotherapy on women's quality of life, noting both emotional and physical challenges.